Table 3.
Activity of different antimicrobials against Pseudomonas aeruginosa collected in Spain in the SMART study (2016-2018)
Antimicrobial | No. of isolates tested | Range | MIC50 | MIC90 | S (susceptible, standard dose) |
I (susceptible, increased exposure) |
R (resistant) |
---|---|---|---|---|---|---|---|
Piperacillin-tazobactam | 925 | ≤2/4 - >64/4 | 8/4 | >64/4 | -- | 66.8 | 33.2 |
Ceftazidime | 925 | ≤1 - >32 | 4 | >32 | -- | 71.8 | 28.2 |
Cefepime | 925 | ≤1 - >32 | 4 | 32 | -- | 72.3 | 27.7 |
Ceftolozane-tazobactam | 925 | ≤0.12/4 - >32/4 | 1/4 | 4/4 | 93.0 | -- | 7.0 |
Ceftazidime-avibactama | 217 | ≤0.12/4 - >32/4 | 2/4 | 8/4 | 94.0 | -- | 6.0 |
Aztreonam | 925 | ≤1 - >16 | 8 | >16 | -- | 79.7 | 20.3 |
Imipenem | 925 | ≤0.12 - >32 | 1 | 16 | -- | 75.5 | 24.5 |
Meropenem | 925 | ≤0.12 - >32 | 0.5 | 16 | 74.7 | 14.0% | 11.3 |
Tobramycina | 217 | <= 0.5 - >8 | ≤0.5 | >8 | 77.4 | -- | 22.6 |
Amikacin | 925 | ≤4 - >32 | ≤4 | 8 | 94.6 | -- | 5.4 |
Ciprofloxacin | 925 | ≤0.25 - >2 | ≤0.25 | >2 | -- | 63.5 | 36.5 |
Levofloxacin | 925 | ≤0.5 - >4 | ≤1 | >4 | -- | 56.0 | 44.0 |
Colistin | 925 | ≤1 - >4 | ≤1 | ≤1 | 99.3 | -- | 0.7 |
Data are only for 2018